Q3 2024 EPS Estimates for The Joint Corp. Decreased by Analyst (NASDAQ:JYNT)

The Joint Corp. (NASDAQ:JYNT) – Equities researchers at Roth Capital lowered their Q3 2024 earnings per share (EPS) estimates for shares of Joint in a research report issued on Thursday, May 2nd. Roth Capital analyst G. Kelly now anticipates that the company will earn $0.09 per share for the quarter, down from their prior forecast of $0.10. The consensus estimate for Joint’s current full-year earnings is $0.13 per share. Roth Capital also issued estimates for Joint’s Q4 2024 earnings at $0.16 EPS, Q1 2025 earnings at $0.11 EPS, Q2 2025 earnings at $0.17 EPS and Q4 2025 earnings at $0.24 EPS.

A number of other research firms have also recently commented on JYNT. TheStreet cut Joint from a “c-” rating to a “d” rating in a research note on Thursday, March 7th. B. Riley increased their price target on Joint from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Monday. StockNews.com upgraded Joint from a “hold” rating to a “buy” rating in a research note on Monday. Finally, Roth Mkm reiterated a “buy” rating and issued a $16.00 price target (up from $13.00) on shares of Joint in a research note on Friday, May 3rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Joint Price Performance

Shares of NASDAQ JYNT opened at $16.13 on Monday. The business has a fifty day moving average price of $12.30 and a 200 day moving average price of $10.27. Joint has a 1-year low of $7.31 and a 1-year high of $16.39. The stock has a market capitalization of $240.98 million, a P/E ratio of -21.51 and a beta of 1.58.

Joint (NASDAQ:JYNT) last issued its quarterly earnings data on Thursday, March 7th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. The firm had revenue of $30.61 million during the quarter, compared to analysts’ expectations of $29.63 million. Joint had a positive return on equity of 3.94% and a negative net margin of 9.24%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Quantbot Technologies LP increased its holdings in shares of Joint by 345.0% in the third quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock valued at $37,000 after purchasing an additional 3,233 shares during the period. Barclays PLC increased its holdings in shares of Joint by 29.4% in the third quarter. Barclays PLC now owns 13,725 shares of the company’s stock valued at $123,000 after purchasing an additional 3,119 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Joint by 43.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 16,506 shares of the company’s stock worth $148,000 after acquiring an additional 4,987 shares during the period. Avondale Wealth Management grew its holdings in Joint by 192.3% during the first quarter. Avondale Wealth Management now owns 19,000 shares of the company’s stock worth $248,000 after acquiring an additional 12,500 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in Joint during the third quarter worth about $179,000. 76.88% of the stock is owned by institutional investors and hedge funds.

About Joint

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.